Form 4: Ventyx Biosciences CEO Converts Holdings Post-Eli Lilly Merger

Ventyx Biosciences, Inc. CEO Raju Mohan converted all common stock, restricted stock units, and eligible stock options into cash following the merger with Eli Lilly and Company.

Summary

• Raju Mohan, CEO, President, Director, and 10% Owner of Ventyx Biosciences, Inc., reported changes in beneficial ownership due to the merger.
• Ventyx Biosciences, Inc. merged with RYLS Merger Corporation, a wholly-owned subsidiary of Eli Lilly and Company, becoming a wholly-owned subsidiary of Eli Lilly.
• Common stock was automatically converted into the right to receive $14.00 per share in cash.
• Unvested Restricted Stock Units (RSUs) were cancelled and converted into a cash award based on the total number of shares subject to the RSU multiplied by $14.00, less applicable withholding taxes.
• Stock options with an exercise price less than or equal to $14.00 were cancelled and converted into a cash amount equal to the total number of shares subject to the option multiplied by the excess of $14.00 over the exercise price, less applicable withholding taxes.
• Stock options with an exercise price greater than $14.00 were fully vested and automatically cancelled for no consideration.
• Following the merger, Raju Mohan's beneficial ownership of Ventyx Biosciences securities is 0.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Ventyx Biosciences shareholders who received cash for their shares and eligible options, though some option holders received no consideration. The completion of the merger provides certainty.

Positives

• Shareholders received a fixed cash payment of $14.00 per share for their common stock.
• Holders of unvested Restricted Stock Units (RSUs) and in-the-money stock options received cash consideration.
• The merger provides a clear exit strategy and liquidity for Ventyx Biosciences shareholders.

Negatives

• Stock options with an exercise price greater than $14.00 were cancelled for no consideration, resulting in no value for those specific holdings.
• Ventyx Biosciences, Inc. ceases to be an independent publicly traded entity.

Future Outlook

The filing indicates the completion of the merger, with Ventyx Biosciences becoming a wholly-owned subsidiary of Eli Lilly and Company. There are no forward-looking statements regarding Ventyx's future as an independent entity.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly and Company of Ventyx Biosciences, a clinical-stage biotechnology company, aligns with a broader trend of larger pharmaceutical companies acquiring smaller biotech firms to bolster their pipelines and gain access to innovative therapies. This particular transaction provides Eli Lilly with Ventyx's assets, potentially in immunology or inflammatory diseases, which are key areas of focus for major pharmaceutical players.

Comparison to Industry Standards

• StockSavvy.ai observes that the $14.00 per share cash consideration represents a specific valuation for Ventyx Biosciences.
• Without the full merger agreement or prior market data, a direct comparison to similar biotech acquisitions (e.g., Pfizer's acquisition of Seagen for $43 billion, or Merck's acquisition of Acceleron Pharma for $11.5 billion) is difficult without knowing the premium paid over Ventyx's pre-announcement share price.
• Cash-only mergers are common for providing immediate liquidity to target company shareholders.

Management Changes

Stakeholder Impact

• Shareholders: Received $14.00 per share in cash for common stock, and cash for eligible RSUs and stock options.
• Employees (specifically Raju Mohan): His equity holdings were converted to cash or cancelled as part of the merger.
• Ventyx Biosciences as an entity: Ceased to be an independent public company, becoming a subsidiary of Eli Lilly.

Key Dates

Recommendation

The company has been acquired by Eli Lilly and Company, and its common stock has been converted into a fixed cash amount of $14.00 per share. There is no longer a public market for Ventyx Biosciences shares, so any remaining shares should be sold to realize the cash consideration.

Keywords

Ventyx Biosciences, VTYX, Eli Lilly, Merger, Form 4, Insider Transaction, Raju Mohan, Acquisition, Common Stock, Restricted Stock Units, Stock Options